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Abstract 
Background: In the European Union (EU), a medicinal product needs a 
marketing authorization (MA) to be placed on the market. The EU’s medicinal 
products’ legislative framework allows for a reduced application for medicines 
outside their data exclusivity. One such type of application is the well-
established use (WEU) medicinal product application (i.e. bibliographic 
applications). Recently, these MA applications have been subject to arbitration 
procedures at the European Medicines Agency’s Committee for Medicinal 
Products for Human Use (CHMP) because of disagreements between member 
states during the authorisation process. This paper reflects on these cases and 
highlights their potential impact on future WEU applications.  
Methods: Decisions adopted by the European Commission on WEU 
applications between 2009 and 2012 were identified from the EU Community 
Register on medicinal products for human use. Subsequently, decisions were 
reviewed to understand the potential serious risk to public health (PSRPH) that 
EU regulators raised during MA application procedures. 
Results: Four decisions were adopted by the EU commission between 2009 
and 2012. Three followed disagreements between member states on PSRPH 
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grounds. One decision was the outcome of a centralised marketing 
authorisation application. Six key messages were identified from the four cases 
reviewed and presented.  
Conclusion: A guideline on WEU to implement the technical specifications to 
fulfil Annex I of Directive 2001/83/EC for MA applications is not available. Thus, 
reflections on recent decisions on WEU applications provide scientific direction 
to the industry as well as the medicinal product regulators on the documentation 
required to successfully file and obtain a WEU MA. 
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Introduction 
Novelty of the Work 
In the EU, one type of medicinal product approval license is the one for old active 
substances (the Well-Established Use (WEU) application file). Unlike generic applications, 
to date there is no official EU guideline on the requirements for WEU products. The only 
guidance available arises from Commission decisions following arbitration at the European 
Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). This 
manuscript reviews these arbitration cases and their implications for the industry 
developing WEU medicinal products. 
Background 
In the European Union (EU), a medicinal product needs a marketing authorization to be 
placed on the market. To obtain this authorisation, an application consisting of a dossier 
supporting the medicinal product’s quality, safety, and efficacy needs to be submitted to 
regulatory authorities. The dossier can either be a full stand-alone dossier consisting of the 
results of the studies (clinical and preclinical as well as quality) conducted by the 
prospective marketing authorisation holder usually for an “on patent” medicinal product 
(originator/innovator medicine) or a dossier consisting of a full package of quality 
documentation, but a reduced clinical and preclinical program. The latter is usually the 
case for medicines outside of their data exclusivity, such as generics, well-established use 
medicinal products, hybrid (mixed bibliographic applications), and biosimilar medicinal 
products. In the case of generics and biosimilars (“biogenerics”), applicants make a bridge 
to the reference medicinal product’s data supporting efficacy and safety contained within 
the reference medicinal product’s dossier.  
Well-established use (WEU) medicinal product dossiers (i.e. bibliographic applications) 
need to fulfil the legislative requirements of Directive 2001/83/EC by showing that the 
medicinal product to be placed on the market is safe and efficacious as well as of good 
quality. This is demonstrated by the reference to appropriate bibliographic data, as well as 
a demonstration that the active substance(s) of the medicinal product have been in use 
within the EU for at least ten years, in terms of the conditions set out in Annex I of 
Directive 2001/83/EC [1], which requires evidence of recognised efficacy, together with an 
acceptable level of proven safety. The WEU route of obtaining a marketing authorisation in 
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the EU is established by Article 10a of Directive 2001/83/EC. The WEU route has been 
used in certain cases as a legal basis for the registration of medicinal products when a 
reference medicinal product cannot be identified in the EU [2]. If a reference medicinal 
product can be identified, then prospective applicants should pursue a development 
program and submit an application file as a generic medicinal product. The WEU route for 
obtaining a marketing authorisation in the EU is not as common as the generic route. The 
EU Mutual Recognition Index product database lists 530 EU bibliographic procedures (i.e. 
WEU procedures) that have been processed (data as of 19 March 2013) [3]. Hence, 
although not as common as generic products (the MRI database lists 19,389 products (this 
value includes generics and mixed bibliographic as well as WEU applications (data as of 
19 March 2013)), the WEU applications are not uncommon in the EU regulatory system. 
Some have recently been subject to referral procedures to the CHMP because of 
disagreements between member states during authorisation procedures. This paper 
reflects and should stimulate debate on recent decisions published by the European 
Commission on WEU applications. The examples are selected based on opinions adopted 
by the CHMP on a centralised procedure as well as the arbitration of decentralised and 
mutual recognition procedures, and the implications for Marketing Authorisation Holders 
are discussed. 
Methods  
Decisions adopted by the European Commission on WEU applications between 2009 and 
2012 were identified from the EU Community Register listing all medicinal products  
for human and veterinary use. See http://ec.europa.eu/health/documents/community-
register/html/index_en.htm [4]. Adopted decisions contain the opinion of the CHMP upon 
which the decision was based. We reviewed the decisions and highlight their potential 
impact on future WEU applications. 
Results  
Four decisions were adopted by the European Commission between 2009 and 2012. 
Three decisions were the result of scientific arbitration at the CHMP following 
disagreements between member states on Potential Serious Risk to Public Health grounds 
within a Mutual Recognition/Decentralised Procedure for a marketing autrhorisation. One 
decision was the outcome of a centralised marketing authorisation application. 
Case Reports 
Ribavirin Capsules and Ribavirin Tablets, iQur Ltd (DK/H/1081/01 – 04/DC) [4, 5] 
The above products were referred to the CHMP in December 2007 under Article 29(4) of 
Directive 2001/83/EC. On 24/10/2008, the European Commission published a decision 
refusing the marketing authorisation for the Ribavirin capsules and Ribavirin tablets. The 
grounds for refusal were based on considerations that the Applicant did not provide 
sufficient evidence for a systematic and documented use of the substance outside (a) 
clinical trials, (b) compassionate use (that is for products used following an official opinion 
given at CHMP for products under evaluation), and (c) named patient supply to 
demonstrate the well-established use of Ribavirin in the claimed indication in the European 
Economic Area (EEA). The Applicant also failed to sufficiently demonstrate the relevance 
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to Ribavirin iQur of the bibliographic data submitted, which included products different from 
the medicinal product intended for marketing [5].  
Drivers for this Commission decision included the fact that the bibliographical data 
submitted related to various Ribavirin-containing products (and therefore different 
formulations), which makes it very difficult to extrapolate the published data to Ribavirin 
iQur (this is of a special concern for clinical trials that may have used experimental 
formulations) intended for marketing, with regards to therapeutic indication, posology, 
duration of treatment, and patient population. Moreover, the literature provided to 
substantiate the WEU of Ribavirin in the claimed indication and was not adequate for at 
least ten years in the EEA. The evidence to meet the criteria of extensive clinical use 
outside clinical trials, compassionate use (that is for products used in practice following an 
official opinion given at CHMP for products under evaluation), and named patient supply in 
the claimed indication was not demonstrated. In fact, the bibliography relevant to the 
indication applied for and referred to by the Applicant consisted of pilot studies conducted 
in small cohorts of patients (mostly non-responders or relapsed patients) receiving the 
combination therapy with Interferon. The CHMP concluded that the application for 
Ribavirin iQur did not satisfy the requirement of the WEU legal basis and recommended 
the refusal of the granting of a marketing authorisation [5]. 
Dexamethasone Oral Solution, Alapis SA – EMEA/H/A-29/1308 [4, 6] 
The above product was referred to the CHMP in May 2011 under Article 29(4) of Directive 
2001/83/EC. On 24/10/2011, the European Commission published a decision allowing the 
granting of a marketing authorisation for Dexamethasone oral solution, Alapis SA. The 
reason the product was referred for arbitration was because some member states involved 
in the procedure considered that the literature data on Dexamethasone tablets that had 
been submitted could not be extrapolated to Dexamethasone oral solution without 
adequate bridging data. According to the member states who disagreed with the reference 
member state and other concerned member states, the safety and efficacy of 
Dexamethasone Alapis could not be established without this bridging data. The 
documentation submitted in the application file showed that Dexamethasone has been 
widely used in EU clinical practice for numerous decades for a number of indications [6]. 
Over 180 literature reports (Randomized Clinical Trials (RCTs); Reviews, Monographs 
(Martindale) etc.) were included in the application dossier. However, the vast majority of 
publications were with tablet formulations and a few with oral solution/syrups [6]. Literature 
data available on the various routes of administration for the same treatment show that 
Dexamethasone is equally effective via any route of administration and that 
Dexamethasone has a broad therapeutic index. However, as information on the 
composition of the Dexamethasone syrup, elixir, or oral solution investigated in the 
provided studies was missing in all the submitted articles, the issue on whether those data 
could be considered as sufficient to allow bridging of the data between the tablets and the 
oral formulation applied for was raised. Additional bridging data between the bibliographic 
data and the proposed pharmaceutical product were therefore requested [6]. The 
Applicant applied for a BCS (Biopharmaceutics Classification System)-based biowaiver 
according to the Appendix II of the “Guideline on the investigation of bioequivalence 
(CPMP/EWP/QWP/1401/98 Rev 1/Corr)” [7], In order to extrapolate efficacy and safety 
data from the bibliographic data in the application file to the oral solution formulation 
applied for, the Applicant provided data that showed that irrespective of the immediate-
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release oral dosage formulation (tablet or solution), the bioavailability of Dexamethasone, 
in terms of extent and rate of absorption, was similar. This was done through 1) a parallel 
artificial membrane permeability assay (PAMPA) data study, 2) literature, and 3) 
dissolution data, demonstrating that the Dexamethasone drug substance has bio-
pharmaceutical characteristics of BCS Class I/III, and that the excipients have no adverse 
effects on bioavailability. The Applicant showed that Dexamethasone Alapis met all criteria 
for a BCS-based biowaiver [6]. This comprehensive package of literature data, supported 
by the requested data collected by the Applicant, enabled the CHMP to conclude on a 
positive benefit/risk balance for the product and recommend the marketing authorisation of 
Dexamethasone Alapis to the European Commission (EC). 
Loraxin Vitabalans Oy (Loratadine, 10 mg Tablets) – EMEA/H/A-29/1325 [4, 8] 
The above product was referred to the CHMP in December 2011 under Article 29(4) of 
Directive 2001/83/EC. On 20/12/2012, the European Commission published a decision 
refusing the marketing authorisation for Loraxin Vitabalans Oy, 10 mg tablets. The reason 
the product was referred for arbitration was because some member states considered that 
the literature data submitted could not ascertain the safety and efficacy of the medicinal 
product intended to be placed on the market. Although there was no issue with 
establishing that loratadine has been in WEU in the EU over the last decade, for most of 
the clinical trials cited by the Applicant supporting efficacy and safety, the medicinal 
product used (and therefore its formulation) within these studies was not clearly defined 
[8]. These studies included loratadine products in several strengths from 5 mg up to 40 
mg. In these studies, pharmacokinetic parameters have been studied after a single dose 
as well as after repeated administration. The studies were conducted in children, healthy 
adult volunteers, and renally impaired patients [8]. In order to bridge the bibliographic data 
cited to Loraxin, the Applicant referred to pharmaceutical, pharmacokinetic, and clinical 
data. From a pharmaceutical perspective, the Applicant argued that the literature on the 
originator product is relevant for their product on the basis of the submitted pharmaceutical 
data. This was not upheld by the CHMP, who considered that since loratadine is not a 
BCS class I (high solubility-high permeability) or III (high solubility-low permeability), drug 
extrapolation based on the pharmaceutical data is not considered scientifically valid. The 
Applicant also submitted pharmacokinetic study data (Report V-808), which was evaluated 
by CHMP [8]. The inclusion of pharmacokinetic data in support of a WEU application is 
allowed, if it is intended to show the relevance of the literature used to demonstrate safety 
and efficacy with regards to the product concerned. The pharmacokinetic study provided to 
bridge Loraxin to the published literature and the AUCt and Cmax of Loraxin to the 
originator product Clarityn did not conform to the acceptance interval of 0.8–1.25 for the 
parent compound, loratadine. Based on the study results used to bridge Loraxin to the 
published literature, there is a potential for difference in exposure after Loraxin 
administration as compared to the product Clarityn, and the Marketing Authorisation 
Holder had not adequately justified why this potential difference in exposure would be 
unlikely to lead to a clinically significant difference in efficacy and/or safety. Searching the 
Pubmed database for loratadine retrieves many publications on Clarityn. Therefore, as the 
Applicant in this application had cited these studies, the data evaluated by the CHMP 
could have been classified as “a single source bibliographic data (i.e. carried out with 
reference product)” and in consequence this product failing the bioequivalence study could 
be considered as a failed generic medicinal product. In conclusion, the CHMP considered 
that the pharmaceutical, pharmacokinetic, and clinical data/documentation referred to by 
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the Applicant was not sufficient to establish the relevance of the bibliographic data to the 
product applied for and no recommendation for a marketing authorisation should be 
expressed [8]. 
Orphacol; Laboratoires CTRS (Cell Therapies Research & Services) EMEA/H/C/1250 [4,9] 
Orphacol "cholic acid" was a designated orphan medicinal product [10] in the following 
indication: treatment of inborn errors in primary bile acid synthesis. In October 2009, 
Laboratoires CTRS submitted a centralised application procedure for a marketing 
authorisation for the following indications: treatment of inborn errors in primary bile acid 
synthesis due to 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-Oxo-
steroid-5β-reductase deficiency in infants, children, and adolescents aged 1 month to 18 
years and adults [9]. The application was a WEU application with bibliographic data 
supporting efficacy and safety. The application also referred to the existence of 
exceptional circumstances in accordance with Article 14(8) of the Regulation (EC) No 
726/2004, due to the rarity of the conditions that the product intends to treat, as well as the 
inability to collect comprehensive information, because it would be contrary to medical 
ethics [11,12]. On 16 December 2010, the CHMP recommended the granting of a 
marketing authorisation under exceptional circumstances in accordance with Article 14(8) 
of Regulation (EC) No 726/2004 [11]. The rationale behind the CHMP’s opinion was due to 
the position that the few patients reported in the literature were considered sufficiently 
representative of the EU patient population [9]. Since the collection of further data in this 
population is not feasible, the CHMP considered that it would be contrary to generally 
accepted principles of medical ethics to collect such information. However, the European 
Commission (EC) refused to grant the marketing authorisation based on the following 
reason: applications for a marketing authorisation must contain specifically and completely 
the particulars and documents as referred to in Articles 8(3), 10, 10a, 10b, or 11 and 
Annex I to Directive 2001/83/EC [1]. The Commission further explained that the 
requirement that marketing authorisation applications contain adequate data is 
fundamental to ensure the quality, efficacy, and safety of medicinal products [9]. Thus. the 
standard data requirements set out in Annex I of Directive 2001/83 need to be complied 
with. Therefore, the EC concluded that a WEU application supported by clinical studies 
based on exceptional circumstances was not legally compatible with the Directive. 
However, on 4 July 2013, the Commission was ordered by the European Court of Justice 
(ECJ) to reverse its decision to refuse to authorise Orphacol [9].  
Discussion 
The WEU application is a type of application for the authorisation of medicinal products in 
the EU. Across the EU, more than 500 medicinal products (please note that we have 
grouped the products: i.e. per strength and pack size is reported as 1 product) have been 
approved through the legal basis of WEU. This makes the WEU route not an unusal 
procedure in relative terms and disagreements between member states during mutual 
recognition/decentralised procedures have resulted in a number of arbitrations at the 
CHMP over the last couple of years. The applicable guideline on the WEU application file 
is the European Commission’s Notice to Applicants. However, a specific guideline on WEU 
and the technical specifications to fulfil Annex I of Directive 2001/83/EC is not available. 
This does not mean that such a guideline is required or needs to be developed, as EU 
regulators have managed to handle many WEU application files over the years. Yet in this 
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scenario, the review of cases at CHMP takes more prominence as it sets the scene of the 
current understanding of the WEU application and how applications will be assessed. The 
four cases reviewed in this paper are extremely interesting and each case enhances the 
understanding of what a WEU application should address. Key points identified (see 
conclusion) from the outcomes on these WEU applications are important for 
manufacturers of medicinal products intending to submit a WEU application to EU 
regulators so that they can submit a successful application. To the best of our knowledge, 
this is the first review of WEU applications referred for arbitration to the CHMP during the 
scientific evaluation of marketing authorisation applications since the CHMP was set up 
[11]. The aim of this review is to identify the challenges faced with WEU applications in 
order to help reduce unnecessary and avoidable delays in otherwise safe and effective 
medicines reaching the EU market. This will ultimately be of benefit to patients. 
Conclusion 
The cases reviewed in this paper enhance the understanding of what a successful WEU 
marketing authorisation application should address.  
The following key points have been identified from the four cases and should help the 
industry improve the quality of their submissions for marketing authorisations based on 
WEU in the EU:  
• in order to fulfil the WEU legal basis, extensive clinical use outside clinical trials (this 
is only applicable for WEU orphan medicinal products [as a process introduced by 
the EU’s orphan legislation]), compassionate use (that is for products used following 
an official opinion given at CHMP for products under evaluation), and named patient 
supply, in the claimed indication, needs to be demonstrated.  
• the inclusion of multi-source bibliographical data with various different formulations 
in the application file can make it very difficult to extrapolate the published data to 
the product applied for. 
• the inclusion of single source bibliographical data (i.e. with only one formulation) 
makes it easier to extrapolate the published data to the product applied for, 
although in some cases a clinical study [only bioequivalence study allowed] 
showing the pharmacokinetic similarity might be required to bridge the 
bibliographical data. 
• in a WEU application file, a bridge needs to be established between the literature 
and the product applied for. To be able to create this bridge, the applicant can use 
data from pharmacokinetic studies it has carried out. These studies could establish 
and support the bridge to the literature cited; furthermore, pharmacokinetic 
parameters should meet the acceptance criteria defined in the EU bioequivalence 
Note for Guidance.  
• If scientifically justified, the use of the BCS-based biowaiver can also be applied in 
WEU applications and is not only scientifically valid for a generic application. The 
“Guideline on the investigation of bioequivalence (CPMP/PWP/EWP/1401/98 Rev 
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1/Corr)” Annex is useful to set what criteria are applicable for a BCS-based 
biowaiver [7]. 
• The European Court of Justice’s ruling on Orphacol has demonstrated that it is 
possible for a marketing authorisation to be granted under exceptional 
circumstances for an orphan medicinal product using the WEU legal basis where 
issues of public health need are identified [9, 13]. 
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